Oct. 08, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company specializing in the development and commercialization of ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

At close: November 8 at 4:00 PM EST ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.61 per share, missing the Zacks Consensus Estimate of $1.66 per share. This compares to earnings of $1.34 per share a year ago.

Featured here, the Balance Sheet for Vivos Therapeutics Inc, which summarises the company's financial position including assets, liabilities and shareholder equity for each of the latest 10 period ...

As we approach the Vivos Therapeutics, Inc. 2024 Annual Meeting of Stockholders on November 26, 2024 at 10:00 a.m. Mountain time, I am pleased to report the progress we have made over the past 12 ...